PFE

Pfizer, Inc.

44.08
USD
-1.10%
44.08
USD
-1.10%
40.94 61.71
52 weeks
52 weeks

Mkt Cap 245.89B

Shares Out 5.58B

Chat
Send me real-time posts from this site at my email

Haleon not a party to U.S. litigation focused on Zantac - spokesperson

LONDON, Aug 11 (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday. "We have never marketed Zantac in any form in the U.S., as Haleon or as GSK consumer healthcare," the spokesperson said, responding to Reuters queryinga near-20% decline in Haleon's share price this week. The spokesperson said the drug has been sold by several companies since 1995 andthat "may make third parties liable ahead of any Haleon exposure." Zantac was marketed by GSK GSK.L between 1995 and 1998, by PfizerPFE.N from 2000 to 2006, by Johnson & JohnsonJNJ.N from 2006 to 2017, and by SanofiSASY.PA between 2017 and 2019, Redburn analysts wrote in a note. GSK and Pfizer have each served Haleon with notice of potential claims of indemnification - but indemnification has not yet been determined between the parties, the Haleon spokesperson said. Given Haleon was formed in 2019 and became an independently listed business only last month, the company "is not primarily liable for any claim," the spokesperson added. (Reporting by Natalie Grover in London;) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue